Skip to main content

Table 1 Summary of tumor-to-background ratios

From: A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

Cell line Number Tumor-to-background [ 11 C]erlotinib Number Tumor-to-background [ 18 F]afatinib
Unblocked
  A549 1 1.0 ± 0.3 4 1.5 ± 0.3*
  H1975 2 0.9 ± 0.3 5 0.8 ± 0.2
  HCC827 3 1.9 ± 0.5* 6 2.3 ± 0.4*
Tariquidar blocked (15 mg/kg)
  A549 7 1.2 ± 0.3 10 1.3 ± 0.3*
  H1975 8 1.0 ± 0.2 11 0.8 ± 0.2
  HCC827 9 1.8 ± 0.3* 12 1.9 ± 0.4*
  1. Comparison of tumor-to-background ratios in non-blocked (1 to 6) and blocked situation (7 to 12) ratios determined in the last frame of the scans (60 to 90 min for [11C]erlotinib and 90 to 120 min for [18F]afatinib) and averaged over three animals. P-gp blocking was performed with 15 mg/kg tariquidar. *Tumor-to-background is statistically significant (P < 0.05, Student’s t-test for paired data). Mutations: A549 (wild type), H1975 (L858R/T790M), and HCC827 (exon 19 deletion).